Yakult Singapore joins virtual Pink Ribbon Walk 2021 to raise awareness for breast cancer
SINGAPORE, Dec. 3, 2021 /PRNewswire/ -- Yakult Singapore is taking part in the virtual edition of the Pink Ribbon Walk organised by the Breast Cancer Foundation (BCF) from 1st to 31st December 2021. This event honours breast cancer survivors, remembers those who have lost their lives and aims to raise awareness and funds to serve the breast cancer community...
Decode Genetics Publishes the Largest Ever Study of the Plasma Proteome
REYKJAVIK, Iceland, Dec. 3, 2021 /PRNewswire/ -- In a study published today in Nature genetics, scientists at deCODE genetics , a subsidiary of the pharmaceutical company Amgen, demonstrate how measuring the levels of a large number of proteins in plasma at population scale when combined with data on sequence diversity and RNA expression dramatically increases insights into human diseases...
Hepagene Therapeutics Initiates the RISE Study, a Phase IIa Clinical Trial of HPG1860 in Patients with NASH
SHANGHAI, Dec. 2, 2021 /PRNewswire/ -- Hepagene Therapeutics, Inc, a clinical stage biopharmaceutical company focusing on innovative therapies for patients with liver diseases, today announced that it has screened the first patient in the USA for the RISE study, a Phase IIa clinical trial of HPG1860 in patients with non-alcoholic steatohepatitis (NASH). HPG1860, a non-bile acid, potent, selective and...
MingMed Biotechnology Announces U.S. FDA Approval for IND Application of HPK1 Small Molecule Inhibitor PRJ1-3024, and Completion of Phase I Clinical Trials for Dry AMD Treatment Drug QA102
GUANGZHOU, China, Dec. 2, 2021 /PRNewswire/ -- MingMed Biotechnology, a clinical stage company dedicated to developing first-in-class pharmaceutical products, announced recently the US Food and Drug Administration (FDA) has approved its Investigational New Drug (IND) application for PRJ1-3024, a HPK1 small-molecule inhibitor for cancer immunotherapy. Dr. Xuebin Liao, a professor of Pharmaceutical Science at Tsinghua University and a...
Clarity and Cardinal Health enter into Agreement for Targeted Copper Theranostics
SYDNEY, Dec. 2, 2021 /PRNewswire/ -- Clarity Pharmaceuticals (ASX: CU6) ("Clarity"), a clinical-stage radiopharmaceutical company developing next-generation products to address the growing needs in oncology, and Cardinal Health (NYSE: CAH), are pleased to announce that the companies have entered into an agreement covering Clarity's Targeted Copper Theranostics (TCT) platform. Cardinal Health will provide...
Rayence’s Low-Dose Detector “GreenON” Receives Critical Acclaim at RSNA 2021
SEOUL, South Korea, Dec. 2, 2021 /PRNewswire/ -- Rayence(www.rayence.com) reported that its low-dose detectors "GreenON" received critical acclaim at the RSNA(Radiological Society of North America) 2021. Rayence at RSNA 2021 At the conference, Rayence exhibited a portfolio of products built on its proprietary low-dose technology, including x-ray detectors and software solutions, under the slogan "Better Dose for...
Joint CUHK-HKU study discovers efficacy of COVID-19 vaccines correlates with a probiotic bacterium, Bifidobacterium adolescentis
HONG KONG, Dec. 2, 2021 /PRNewswire/ -- The Centre for Gut Microbiota Research of the Faculty of Medicine at The Chinese University of Hong Kong (CU Medicine) is among the first in the world to discover that germs in our gut (gut microbiota) modulate our immunity and disease severity in COVID-19. In...
DiNovA Medtech Announces Mr. Yaniv Kirma to Join as DiNovA Israel Incubator’s Chief Operating Officer
CAESAREA, Israel, Dec. 2, 2021 /PRNewswire/ -- DiNovA Medtech, a leading medical devices incubator in China ("DiNovA"), is pleased to announce Mr. Yaniv Kirma, to come on board as Chief Operating Officer of DiNovA Israel Incubator ("DiNovA Israel"). Mr. Kirma will join force with Chief Medical Officer Prof. Chaim Lotan to lead the effort at DiNovA Israel to promote...
Publication in The New England Journal of Medicine Confirms that Tens of Thousands of Women with Node-positive, Early-stage Breast Cancer Can Avoid Chemotherapy with the Oncotype DX® Test
- RxPONDER, an independent study led by SWOG Cancer Research Network, demonstrates that guiding treatment with Oncotype DX test can spare chemotherapy use in majority of postmenopausal women - Results have already led to updated NCCN Guidelines® for breast cancer - New RxPONDER results to be featured in oral presentation at...
DoctorOnCall Partners Up With Qualitas Group to Bolster Booster Vaccination Drive
KUALA LUMPUR, Malaysia, Dec. 2, 2021 /PRNewswire/ -- DoctorOnCall, Malaysia's first and largest digital health platform today announced its partnership with Qualitas Medical Group to form a collaborative alliance to extend COVID-19 vaccination to the population who are yet to receive it, including foreign nationals and adolescents over the age of 12. The initiative is designed to provide swift,...
